BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fu T, Kim YC, Byun S, Kim DH, Seok S, Suino-Powell K, Xu HE, Kemper B, Kemper JK. FXR Primes the Liver for Intestinal FGF15 Signaling by Transient Induction of β-Klotho. Mol Endocrinol 2016;30:92-103. [PMID: 26505219 DOI: 10.1210/me.2015-1226] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Panzitt K, Wagner M. FXR in liver physiology: Multiple faces to regulate liver metabolism. Biochim Biophys Acta Mol Basis Dis 2021;1867:166133. [PMID: 33771667 DOI: 10.1016/j.bbadis.2021.166133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Unterman TG. Regulation of Hepatic Glucose Metabolism by FoxO Proteins, an Integrated Approach. Forkhead FOXO Transcription Factors in Development and Disease. Elsevier; 2018. pp. 119-47. [DOI: 10.1016/bs.ctdb.2017.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kasahara K, Tanoue T, Yamashita T, Yodoi K, Matsumoto T, Emoto T, Mizoguchi T, Hayashi T, Kitano N, Sasaki N, Atarashi K, Honda K, Hirata KI. Commensal bacteria at the crossroad between cholesterol homeostasis and chronic inflammation in atherosclerosis. J Lipid Res 2017;58:519-28. [PMID: 28130274 DOI: 10.1194/jlr.M072165] [Cited by in Crossref: 59] [Cited by in F6Publishing: 36] [Article Influence: 11.8] [Reference Citation Analysis]
4 Simbrunner B, Trauner M, Reiberger T. Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. Aliment Pharmacol Ther 2021;54:1243-62. [PMID: 34555862 DOI: 10.1111/apt.16602] [Reference Citation Analysis]
5 Somm E, Jornayvaz FR. Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives. Endocr Rev 2018;39:960-89. [PMID: 30124818 DOI: 10.1210/er.2018-00134] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
6 Schumacher JD, Guo GL. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis. Handb Exp Pharmacol 2019;256:325-57. [PMID: 31201553 DOI: 10.1007/164_2019_228] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
7 Gadaleta RM, Moschetta A. DARK AND BRIGHT SIDE OF TARGETING THE FIBROBLAST GROWTH FACTOR RECEPTOR 4 IN THE LIVER. J Hepatol 2021:S0168-8278(21)01958-9. [PMID: 34364916 DOI: 10.1016/j.jhep.2021.07.029] [Reference Citation Analysis]
8 de Boer JF, Schonewille M, Boesjes M, Wolters H, Bloks VW, Bos T, van Dijk TH, Jurdzinski A, Boverhof R, Wolters JC, Kuivenhoven JA, van Deursen JM, Oude Elferink RPJ, Moschetta A, Kremoser C, Verkade HJ, Kuipers F, Groen AK. Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice. Gastroenterology 2017;152:1126-1138.e6. [PMID: 28065787 DOI: 10.1053/j.gastro.2016.12.037] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 13.8] [Reference Citation Analysis]
9 Pak HH, Cummings NE, Green CL, Brinkman JA, Yu D, Tomasiewicz JL, Yang SE, Boyle C, Konon EN, Ong IM, Lamming DW. The Metabolic Response to a Low Amino Acid Diet is Independent of Diet-Induced Shifts in the Composition of the Gut Microbiome. Sci Rep 2019;9:67. [PMID: 30635612 DOI: 10.1038/s41598-018-37177-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
10 Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N, Jelsing J, Young M. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J Gastroenterol 2018; 24(2): 195-210 [PMID: 29375205 DOI: 10.3748/wjg.v24.i2.195] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
11 Alvarez-Sola G, Uriarte I, Latasa MU, Jimenez M, Barcena-Varela M, Santamaría E, Urtasun R, Rodriguez-Ortigosa C, Prieto J, Berraondo P, Fernandez-Barrena MG, Berasain C, Avila MA. Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications. Biochim Biophys Acta Mol Basis Dis 2018;1864:1326-34. [PMID: 28709961 DOI: 10.1016/j.bbadis.2017.06.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
12 Massafra V, van Mil SWC. Farnesoid X receptor: A "homeostat" for hepatic nutrient metabolism. Biochim Biophys Acta Mol Basis Dis. 2018;1864:45-59. [PMID: 28986309 DOI: 10.1016/j.bbadis.2017.10.003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
13 Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, Zhu Q, Zhang T, Leblanc M, Liu S, He M, Waizenegger W, Gasser E, Schnabl B, Atkins AR, Yu RT, Knight R, Liddle C, Downes M, Evans RM. FXR Regulates Intestinal Cancer Stem Cell Proliferation. Cell 2019;176:1098-1112.e18. [PMID: 30794774 DOI: 10.1016/j.cell.2019.01.036] [Cited by in Crossref: 88] [Cited by in F6Publishing: 90] [Article Influence: 44.0] [Reference Citation Analysis]
14 Martinot E, Baptissart M, Véga A, Sèdes L, Rouaisnel B, Vaz F, Saru JP, de Haze A, Baron S, Caira F, Beaudoin C, Volle DH. Bile acid homeostasis controls CAR signaling pathways in mouse testis through FXRalpha. Sci Rep 2017;7:42182. [PMID: 28181583 DOI: 10.1038/srep42182] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
15 Yu Y, Shi X, Zheng Q, Wang X, Liu X, Tan M, Lv G, Zhang P, Martin RC, Li Y. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice. Int J Biol Sci 2021;17:2576-89. [PMID: 34326695 DOI: 10.7150/ijbs.58776] [Reference Citation Analysis]
16 Seok S, Sun H, Kim YC, Kemper B, Kemper JK. Defective FXR-SHP Regulation in Obesity Aberrantly Increases miR-802 Expression, Promoting Insulin Resistance and Fatty Liver. Diabetes 2021;70:733-44. [PMID: 33328206 DOI: 10.2337/db20-0856] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Gadaleta RM, Moschetta A. Metabolic Messengers: fibroblast growth factor 15/19. Nat Metab 2019;1:588-94. [DOI: 10.1038/s42255-019-0074-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
18 Zhou WY, Zheng H, Du XL, Yang JL. Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients. Cancer Biol Med 2016;13:260-8. [PMID: 27458533 DOI: 10.20892/j.issn.2095-3941.2015.0102] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
19 Villalona G, Price A, Blomenkamp K, Manithody C, Saxena S, Ratchford T, Westrich M, Kakarla V, Pochampally S, Phillips W, Heafner N, Korremla N, Greenspon J, Guzman MA, Kumar Jain A. No Gut No Gain! Enteral Bile Acid Treatment Preserves Gut Growth but Not Parenteral Nutrition-Associated Liver Injury in a Novel Extensive Short Bowel Animal Model. JPEN J Parenter Enteral Nutr 2018;42:1238-51. [PMID: 29701901 DOI: 10.1002/jpen.1167] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
20 Chen ML, Takeda K, Sundrud MS. Emerging roles of bile acids in mucosal immunity and inflammation. Mucosal Immunol. 2019;12:851-861. [PMID: 30952999 DOI: 10.1038/s41385-019-0162-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 18.0] [Reference Citation Analysis]
21 Kim YC, Jung H, Seok S, Zhang Y, Ma J, Li T, Kemper B, Kemper JK. MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice. Hepatology 2020;71:2118-34. [PMID: 31549733 DOI: 10.1002/hep.30966] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
22 Byun S, Kim DH, Ryerson D, Kim YC, Sun H, Kong B, Yau P, Guo G, Xu HE, Kemper B, Kemper JK. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis. Nat Commun. 2018;9:2590. [PMID: 29968724 DOI: 10.1038/s41467-018-04697-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
23 Yang W, Chen X, Liu Y, Chen M, Jiang X, Shen T, Li Q, Yang Y, Ling W. N-3 polyunsaturated fatty acids increase hepatic fibroblast growth factor 21 sensitivity via a PPAR-γ-β-klotho pathway. Mol Nutr Food Res 2017;61:1601075. [DOI: 10.1002/mnfr.201601075] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
24 Baptissart M, Sèdes L, Holota H, Thirouard L, Martinot E, de Haze A, Rouaisnel B, Caira F, Beaudoin C, Volle DH. Multigenerational impacts of bile exposure are mediated by TGR5 signaling pathways. Sci Rep 2018;8:16875. [PMID: 30443025 DOI: 10.1038/s41598-018-34863-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
25 Kim YC, Seok S, Zhang Y, Ma J, Kong B, Guo G, Kemper B, Kemper JK. Intestinal FGF15/19 physiologically repress hepatic lipogenesis in the late fed-state by activating SHP and DNMT3A. Nat Commun 2020;11:5969. [PMID: 33235221 DOI: 10.1038/s41467-020-19803-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
26 Hou Y, Fan W, Yang W, Samdani AQ, Jackson AO, Qu S. Farnesoid X receptor: An important factor in blood glucose regulation. Clin Chim Acta 2019;495:29-34. [PMID: 30910597 DOI: 10.1016/j.cca.2019.03.1626] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
27 Guizoni DM, Vettorazzi JF, Carneiro EM, Davel AP. Modulation of endothelium-derived nitric oxide production and activity by taurine and taurine-conjugated bile acids. Nitric Oxide. 2020;94:48-53. [PMID: 31669041 DOI: 10.1016/j.niox.2019.10.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
28 Huang W, Kong D. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. Biomedicine & Pharmacotherapy 2021;135:111235. [DOI: 10.1016/j.biopha.2021.111235] [Reference Citation Analysis]
29 Nobili V, Alisi A, Mosca A, Della Corte C, Veraldi S, De Vito R, De Stefanis C, D'Oria V, Jahnel J, Zohrer E, Scorletti E, Byrne CD. Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. Liver Int. 2018;38:342-349. [PMID: 28746779 DOI: 10.1111/liv.13531] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
30 Schonewille M, de Boer JF, Groen AK. Bile salts in control of lipid metabolism: . Current Opinion in Lipidology 2016;27:295-301. [DOI: 10.1097/mol.0000000000000303] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
31 Jung H, Chen J, Hu X, Sun H, Wu SY, Chiang CM, Kemper B, Chen LF, Kemper JK. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination. JCI Insight 2020;6:141640. [PMID: 33290278 DOI: 10.1172/jci.insight.141640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]